76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Inmode Ltd
Closed
SectorHealthcare
14.04 -0.57
Overview
Share price change
24h
Min
13.83
Max
14.18
Income | -65M 18M |
|---|---|
Sales | -20M 78M |
P/E Sector Avg | 5.955 50.291 |
EPS | 0.31 |
Profit margin | 23.372 |
Employees | 599 |
EBITDA | -12M 16M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +25.36% upside |
Next Earnings | 31 Jul 2025 |
|---|
Market Cap | -128M 839M |
|---|---|
Previous open | 14.61 |
Previous close | 14.04 |
News Sentiment
By Acuity
50%
50%
154 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Inmode Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Inmode Ltd Forecast
Price Target
By TipRanks
25.36% upside
12 Months Forecast
Average 17.25 USD 25.36%
High 24 USD
Low 15 USD
Based on 7 Wall Street analysts offering 12 month price targets forInmode Ltd - Dist in the last 3 months.
Sentiment
By Acuity
154 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Inmode Ltd
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
